Background:
The Indian Patent office had granted a patent
to Avesthagen, an Indian drug maker firm, for a diabetes medicine made from the
extract of jamun, lavangpatti and chundun.
Grounds
of Revocation:
The government has revoked the patent using
a “rarest of rare” provision in the Patents Act saying it was an “integral part”
of traditional medicine. It has said that the patent was “mischievous to the state and
generally prejudicial to the public” as the treatment was an “integral part” of
ayurveda, unani and siddha system of medicine.
Defendant’s
Stand:
Defending the patent the company argued
that the extracts, which work individually in managing diabetes, had an aggressive
effect when combined. In addition, it used an approach that is “innovative,
novel and scientific” in developing a formulation and screened it for efficacy
and safety using modern technology. It has also argued that the patent was not prejudicial
to public interest as it would support Indian farmers, from whom the plants
would be sourced, and provide employment to people.
Future
Outcomes:
While the problem seems to have been
dealt with at least for the moment, there could be more in store as the
government has discovered that there are at least four or five similar
instances of patents given to medicines over the last five years or so that
have been “developed” using commonly used plants and fruits, ranging from amla, methi, karela and ashswangandha.
Conclusion:
The present patent controversy is proving
to be a major embarrassment, given that India has for long fought for
protecting traditional knowledge and genetic resources and sought to check
piracy of ayurvedic and other traditional forms of medicine. What is even more
curious is how the Indian Patents Office gave the protection after the government
had successfully got European authorities to turn down the application two
years ago. The government has put all such patents under scanner and there
would be more patents revocations at offing.
No comments:
Post a Comment